Inhibition of Aurora‑B suppresses osteosarcoma cell migration and invasion

Zhu,Xiao Ping; Liu,Zhi Li; Peng,Ai Fen; Zhou,Yun Fei; Long,Xin Hua; Luo,Qing Feng; Huang,Shan Hu; Shu,Yong

doi:10.3892/etm.2014.1491

Inhibition of Aurora‑B suppresses osteosarcoma cell migration and invasion

Authors:
- Xiao Ping Zhu
- Zhi Li Liu
- Ai Fen Peng
- Yun Fei Zhou
- Xin Hua Long
- Qing Feng Luo
- Shan Hu Huang
- Yong Shu
View Affiliations

Affiliations: Department of Anesthesia, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Orthopedics, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi 330004, P.R. China, Department of Pathology, Cancer Hospital of Jiangxi Province, Nanchang, Jiangxi 330029, P.R. China
Published online on: January 20, 2014 https://doi.org/10.3892/etm.2014.1491
Pages: 560-564

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have suggested that Aurora‑B may be involved in cancer metastasis. However, its role has been poorly evaluated in osteosarcoma (OS). The aim of this study was to investigate the correlation between Aurora‑B expression and metastasis in human OS. The human OS cell line, U2‑OS, and OS biopsy specimens were used in the study. The expression of Aurora‑B protein was examined using immunohistochemistry and western blotting in OS tissues and U2‑OS cells, respectively. AZD1152‑hydroxyquinazoline‑pyrazol‑anilide, an inhibitor of Aurora‑B, was used to inhibit Aurora‑B expression in U2‑OS cells. The effect of Aurora‑B inhibition on U2‑OS cell proliferation, invasion and migration was assessed using MTT, colony formation, wound healing and Transwell assays. The results showed that positive expression of the Aurora‑B protein was observed in the nucleus, and that Aurora‑B expression levels in the cases with pulmonary metastases were significantly higher than in those without metastasis. In vitro, the proliferation, invasion and migration of U2‑OS cells were suppressed by the inhibition of Aurora‑B. These results suggest that Aurora‑B may be involved in OS metastasis, and may be a promising target in the treatment of OS metastasis.

View Figures

View References

1	Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
2	Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, et al: Local recurrence and local control of non-metastatic osteosarcoma of the extremities: A 27-year experience in a single institution. J Surg Oncol. 96:118–123. 2007.PubMed/NCBI
3	Jawad MU, Cheung MC, Clarke J, Koniaris LG and Scully SP: Osteosarcoma: Improvement in survival limited to high-grade patients only. J Cancer Res Clin Oncol. 137:597–607. 2011. View Article : Google Scholar : PubMed/NCBI
4	Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, Marec-Berard P, et al: Metastatic osteosarcoma at diagnosis: Prognostic factors and long-term outcome the French pediatric experience. Cancer. 104:1100–1109. 2005. View Article : Google Scholar : PubMed/NCBI
5	Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss J, Szendroi M, et al: Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. Pediatr Blood Cancer. 57:415–422. 2011. View Article : Google Scholar : PubMed/NCBI
6	Zhang L and Zhang S: ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin. J Obstet Gynaecol Res. 37:591–600. 2011. View Article : Google Scholar : PubMed/NCBI
7	Wang WR, Yang SS, Lin JX, Zeng ZY, Liu DM and Liu HT: Expression of Aurora-B in non-small cell lung cancer and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao. 29:1853–1856. 2009.(In Chinese).
8	Qi G, Ogawa I, Kudo Y, Miyauchi M, Siriwardena BS, Shimamoto F, et al: Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch. 450:297–302. 2007. View Article : Google Scholar : PubMed/NCBI
9	Abdullah AS, Foong C and Murata-Hori M: Specific distribution of overexpressed Aurora-B kinase during interphase of normal epithelial cells. Cancer Cell Int. 5:312005. View Article : Google Scholar : PubMed/NCBI
10	Li Y, Zhou W, Wei L, Jin J, Tang K, Li C, et al: The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma. Int J Oncol. 41:2139–2149. 2012.PubMed/NCBI
11	Tuncel H, Shimamoto F, Kaneko Guangying Qi H, Aoki E, Jikihara H, et al: Nuclear Aurora-B and cytoplasmic Survivin expression is involved in lymph node metastasis of colorectal cancer. Oncol Lett. 3:1109–1114. 2012.PubMed/NCBI
12	Pohl A, Azuma M, Zhang W, Yang D, Ning Y, Winder T, et al: Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer. Pharmacogenomics J. 11:93–99. 2011. View Article : Google Scholar : PubMed/NCBI
13	Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, et al: Antineoplastic effects of an Aurora-B kinase inhibitor in breast cancer. Mol Cancer. 9:422010. View Article : Google Scholar : PubMed/NCBI
14	Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR, Wu HH, et al: Overexpression of Aurora-B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch. 455:431–440. 2009. View Article : Google Scholar : PubMed/NCBI
15	Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, et al: The selective Aurora-B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol. 140:295–302. 2008. View Article : Google Scholar : PubMed/NCBI
16	Adams RR, Eckley DM, Vagnarelli P, Wheatley SP, Gerloff DL, Mackay AM, et al: Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumour cells. Chromosoma. 10:65–74. 2011.PubMed/NCBI
17	Yoon MJ, Park SS, Kang YJ, Kim IY, Lee JA, Lee JS, et al: Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin. Carcinogenesis. 33:492–500. 2012. View Article : Google Scholar : PubMed/NCBI
18	Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF, et al: Aurora kinases in childhood acute leukemia: the promise of Aurora-B as therapeutic target. Leukemia. 27:560–568. 2013. View Article : Google Scholar : PubMed/NCBI
19	Xie F, Lang Q, Zhou M, Zhang H, Zhang Z, Zhang Y, et al: The dietary flavonoid luteolin inhibits Aurora-B kinase activity and blocks proliferation of cancer cells. Eur J Pharm Sci. 46:388–396. 2012. View Article : Google Scholar : PubMed/NCBI
20	Li J, Hu H, Lang Q, Zhang H, Huang Q, Wu Y and Yu L: A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibitingAurora-B kinase activity. Eur J Med Chem. 65:151–157. 2013. View Article : Google Scholar : PubMed/NCBI
21	Yamauchi T, Uzui K, Shigemi H, Negoro E, Yoshida A and Ueda T: Aurora-B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells. Cancer Sci. 104:926–933. 2013. View Article : Google Scholar : PubMed/NCBI
22	Li J, Lang Q, Zhang H, Huang Q and Yu L: S39, a novel Aurora B kinase inhibitor, shows potent antineoplastic activity in human Hela cervical cancer cell line. Biotechnol Lett. 35:853–860. 2013. View Article : Google Scholar : PubMed/NCBI
23	Xie H, Lee MH, Zhu F, Reddy K, Peng C, Li Y, Lim do Y, et al: Identification of an Aurora kinase inhibitor specific for the Aurora-B isoform. Cancer Res. 73:716–724. 2013. View Article : Google Scholar : PubMed/NCBI
24	Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al: AZD1152, a selective inhibitor of Aurora-B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 13:3682–3688. 2007. View Article : Google Scholar : PubMed/NCBI
25	Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, et al: AZD1152, a novel and selective Aurora-B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 110:2034–2040. 2007. View Article : Google Scholar
26	Azzariti A, Bocci G, Porcelli L, Fioravanti A, Sini P, Simone GM, et al: Aurora-B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br J Cancer. 104:769–780. 2011. View Article : Google Scholar : PubMed/NCBI
27	Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, et al: Aurora-B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J Biol Chem. 287:29887–29998. 2012. View Article : Google Scholar
28	Takeshita M, Koga T, Takayama K, Ijichi K, Yano T, Maehara Y, et al: Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. Lung Cancer. 80:85–90. 2013. View Article : Google Scholar : PubMed/NCBI